Two phase 1 studies report encouraging findings with use of novel autologous CAR T-cell therapies in gastrointestinal (GI) malignancies.
Two phase 1 studies report encouraging findings with use of novel autologous CAR T-cell therapies in gastrointestinal (GI) malignancies.